Core Insights - The core focus of the news is the publication of the ENSURE II study results, which evaluates the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for the treatment of chronic hepatitis B virus (HBV) infection [1][2] Group 1: Study Overview - The ENSURE study was conducted in two parts, assessing chronic HBV patients with viral suppression [2] - In the first part, participants who had not received BRII-179 were randomly assigned to either 48 weeks of PEG-IFNα monotherapy or a combination treatment with elebsiran (administered every 4 weeks at doses of 200mg or 100mg) [2] - The second part involved participants who had previously received elebsiran combined with BRII-179, categorized based on their anti-HBs peak levels, and subsequently treated with elebsiran (100mg every 4 weeks) and weekly PEG-IFNα for 48 weeks [2] Group 2: Publication Details - The study results have been published in the peer-reviewed journal Nature Medicine, under the title "elebsiran and PEG-IFNα treatment for chronic hepatitis B virus infection: a partially randomized, open-label phase II clinical trial" [1] - The research also explores the potential role of the therapeutic vaccine BRII-179 in identifying immune responders and enhancing the HBsAg clearance rate [1]
腾盛博药-B(02137.HK)于《自然·医学》发表ENSURE II期研究结果